Last $38.33 USD
Change Today -0.32 / -0.83%
Volume 128.3K
ZFGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 4:00 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

zafgen inc (ZFGN) Snapshot

Open
$38.70
Previous Close
$38.65
Day High
$39.73
Day Low
$38.00
52 Week High
02/23/15 - $43.03
52 Week Low
10/15/14 - $16.01
Market Cap
1.0B
Average Volume 10 Days
174.1K
EPS TTM
--
Shares Outstanding
26.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZAFGEN INC (ZFGN)

Related News

No related news articles were found.

zafgen inc (ZFGN) Related Businessweek News

No Related Businessweek News Found

zafgen inc (ZFGN) Details

Zafgen, Inc., a biopharmaceutical company, focuses on the provision of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical trials reduces the severity of nonalcoholic steatohepatitis and plasma glucose. Zafgen, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

18 Employees
Last Reported Date: 01/23/15
Founded in 2005

zafgen inc (ZFGN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $425.0K
President
Total Annual Compensation: $195.4K
Chief Financial Officer
Total Annual Compensation: $297.9K
Chief Medical Officer
Total Annual Compensation: $407.0K
Chief Commercial Officer
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

zafgen inc (ZFGN) Key Developments

Zafgen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 02:35 PM

Zafgen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 02:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.

Zafgen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM

Zafgen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.

Zafgen Announces Positive Results from Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity

Zafgen announced that ZAF-221, a randomized, double-blind, placebo-controlled Phase 2 clinical trial of beloranib, a MetAP2 inhibitor, in 14 adults with hypothalamic injury associated obesity, or HIAO, met the primary efficacy endpoint of weight reduction (p = 0.01). In addition, beloranib treatment was well-tolerated and improved cardiovascular disease risk factors. HIAO is a rare form of medically induced obesity resulting from damage to the hypothalamus following resection of central nervous system tumors such as craniopharyngioma. The hypothalamus is a homeostatic control center in the brain that provides oversight of multiple hormonal systems, metabolic rate, hunger, and satiety. Patients affected by HIAO fail to regulate metabolism and food intake normally, resulting in rapid and intractable weight gain, treatment resistant severe obesity, and associated co-morbidities. Beloranib, a first-in-class MetAP2 inhibitor, that has demonstrated the potential to address weight loss and hunger reduction in patients with obesity, is being studied for the treatment of multiple indications. ZAF-221 was a randomized, double-blind, placebo controlled study of twice-weekly subcutaneous injections of 1.8 mg beloranib or placebo in patients with HIAO to evaluate weight reduction and safety over four weeks, followed by an optional four week open-label extension. Beloranib treatment resulted in mean weight loss of 3.4 kg and 6.2 kg in patients with HIAO after four and eight weeks of treatment with beloranib, respectively, in contrast to 0.3 kg mean weight loss in patients treated with placebo for four weeks (p= 0.01). Improvements in cardiovascular disease risk factors of lipids and inflammation (measured by C-reactive protein) were also observed. Beloranib 1.8 mg was well tolerated in this population, with no serious or severe adverse events reported. Safety measures such as laboratory, electrocardiogram, and vital sign measurements revealed no signals of concern, and all subjects randomized to beloranib completed the trial. This trial enrolled 14 obese patients (nine women and five men) who were confirmed by magnetic resonance imaging (MRI) to have had hypothalamic injury.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZFGN:US $38.33 USD -0.32

ZFGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZFGN.
View Industry Companies
 

Industry Analysis

ZFGN

Industry Average

Valuation ZFGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZAFGEN INC, please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.